00:51 , Mar 9, 2019 |  BC Extra  |  Clinical News

AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in...
02:39 , Feb 25, 2017 |  BioCentury  |  Politics, Policy & Law

Second wind for importation

Outrage over Marathon Pharmaceuticals LLC ’s pricing of Emflaza deflazacort has breathed new life into proposals for FDA to make it easier to import lower drug prices. Marathon quickly put its commercialization plans for the...
07:00 , Sep 12, 2016 |  BioCentury  |  Politics, Policy & Law

Executive power

Years of congressional gridlock have caused power in Washington to shift to the White House, making the levers of power less accessible to pharmaceutical industry lobbyists. While Congress will continue to mine outrage over drug...
08:00 , Jan 18, 2016 |  BioCentury  |  Politics, Policy & Law

Compounding prices

Joshua Sharfstein, associate dean at the Johns Hopkins Bloomberg School of Public Health, wants to deploy the FDA to battle companies like Turing Pharmaceuticals AG that have enraged the public by obtaining sole U.S. distribution...
08:00 , Feb 9, 2015 |  BioCentury  |  Politics, Policy & Law

Hamburg's legacy

Each FDA Commissioner redefines the job. Margaret Hamburg's goals from the outset were to enhance scientific capacity through hires and better training, make regulatory science a recognized field, boost morale and heal a fractious and...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Lumara Health, AMAG Pharmaceuticals deal

AMAG will acquire Lumara's maternal health business in a cash and stock deal. Lumara (formerly KV Pharmaceutical Co. ) will receive $600 million in cash and 3.2 million AMAG shares worth about $74.4 million based...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

Lumara Health, Perrigo deal

Perrigo will acquire Lumara's OTC women's healthcare business for $82 million in cash. Perrigo will gain Lumara's Clindesse clindamycin phosphate and Gynazole-1 butoconazole nitrate vaginal creams and Evamist estradiol transdermal spray. Perrigo said it plans...
07:00 , Oct 6, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/3 cls AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Price target Outperform 39% $32.27 Jefferies Eun Yang Upgrade Buy (from...
07:00 , Oct 6, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/3 cls AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Price target Outperform 39% $32.27 Jefferies Eun Yang Upgrade Buy (from...
02:30 , Sep 30, 2014 |  BC Extra  |  Company News

AMAG gains on M&A deal to add Makena

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) jumped $6.54 (28%) to $29.72 Monday on news it agreed to acquire the maternal health business of Lumara Health Inc. (Chesterfield, Mo.) -- once known as KV Pharmaceutical Co. -- for...